SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-097249
Filing Date
2021-07-29
Accepted
2021-07-29 07:16:07
Documents
14
Period of Report
2021-07-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2123441d1_8k.htm   iXBRL 8-K 33698
2 EXHIBIT 99.1 tm2123441d1_ex99-1.htm EX-99.1 111051
6 GRAPHIC image_002.jpg GRAPHIC 2324
  Complete submission text file 0001104659-21-097249.txt   343024

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA icpt-20210729.xsd EX-101.SCH 3209
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE icpt-20210729_lab.xml EX-101.LAB 34593
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE icpt-20210729_pre.xml EX-101.PRE 22726
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2123441d1_8k_htm.xml XML 3619
Mailing Address 10 HUDSON YARDS, 37TH FLOOR New York NY 10001
Business Address 10 HUDSON YARDS, 37TH FLOOR NEW YORK NY 10001 646-747-1000
INTERCEPT PHARMACEUTICALS, INC. (Filer) CIK: 0001270073 (see all company filings)

IRS No.: 223868459 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35668 | Film No.: 211124803
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences